{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:33:32Z","timestamp":1792164812983,"version":"4.4.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T00:00:00Z","timestamp":1519603200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00702-018-1860-x","type":"journal-article","created":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T18:31:57Z","timestamp":1519669917000},"page":"953-963","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["An observational study of rotigotine transdermal patch and other currently prescribed therapies in patients with Parkinson\u2019s disease"],"prefix":"10.1007","volume":"125","author":[{"given":"Thomas","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Tolosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letitia","family":"Badea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnaz","family":"Asgharnejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Grieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Markowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Nondonfaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Timmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,26]]},"reference":[{"key":"1860_CR1","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16:448\u2013458","journal-title":"Mov Disord"},{"key":"1860_CR2","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/S1474-4422(07)70218-1","volume":"6","author":"A Antonini","year":"2007","unstructured":"Antonini A, Poewe W (2007) Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson\u2019s disease. Lancet Neurol 6:826\u2013829","journal-title":"Lancet Neurol"},{"key":"1860_CR3","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","volume":"311","author":"BS Connolly","year":"2014","unstructured":"Connolly BS, Lang AE (2014) Pharmacological treatment of Parkinson disease: a review. JAMA 311:1670\u20131683","journal-title":"JAMA"},{"key":"1860_CR4","first-page":"233","volume":"6","author":"K Eggert","year":"2016","unstructured":"Eggert K, Antony G, Anvari K, Behrens S, Dapprich M, Ehret R, Luerr W, Nass A, Pfister RM, Planz-Kuhlendahl S, Reifschneider G, Simonow A, Schwalbe M, Oertel WH (2016) A prospective, multicenter, 2-year echocardiographic study on valvular heart disease in Parkinson\u2019s disease patients taking rotigotine and other non-ergot dopamine agonists. J Alzheimer\u2019s Dis Parkinsonism 6:233","journal-title":"J Alzheimer\u2019s Dis Parkinsonism"},{"key":"1860_CR5","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.parkreldis.2012.01.008","volume":"18","author":"LW Elmer","year":"2012","unstructured":"Elmer LW, Surmann E, Boroojerdi B, Jankovic J (2012) Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson\u2019s disease: a prospective, open-label extension study. Parkinsonism Relat Disord 18:488\u2013493","journal-title":"Parkinsonism Relat Disord"},{"key":"1860_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1468-1331.2012.03866.x","volume":"20","author":"JJ Ferreira","year":"2013","unstructured":"Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G, Dietrichs E, Fabbrini G, Friedman A, Kanovsky P, Kostic V, Nieuwboer A, Odin P, Poewe W, Rascol O, Sampaio C, Schupbach M, Tolosa E, Trenkwalder C, Schapira A, Berardelli A, Oertel WH (2013) Summary of the recommendations of the EFNS\/MDS-ES review on therapeutic management of Parkinson\u2019s disease. Eur J Neurol 20:5\u201315","journal-title":"Eur J Neurol"},{"key":"1860_CR7","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1002\/mds.21741","volume":"22","author":"N Giladi","year":"2007","unstructured":"Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH (2007) Rotigotine transdermal patch in early Parkinson\u2019s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 22:2398\u20132404","journal-title":"Mov Disord"},{"key":"1860_CR8","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.parkreldis.2014.09.016","volume":"20","author":"N Giladi","year":"2014","unstructured":"Giladi N, Ghys L, Surmann E, Boroojerdi B, Jankovic J (2014) Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson\u2019s disease. Parkinsonism Relat Disord 20:1345\u20131351","journal-title":"Parkinsonism Relat Disord"},{"key":"1860_CR9","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/S0140-6736(14)60683-8","volume":"384","author":"R Gray","year":"2014","unstructured":"Gray R, Ives N, Rick C, Patel S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE (2014) Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson\u2019s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 384:1196\u20131205","journal-title":"Lancet"},{"key":"1860_CR10","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/j.1468-1331.2006.01547.x","volume":"13","author":"M Horstink","year":"2006","unstructured":"Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, Larsen JP, Lees A, Oertel W, Poewe W, Rascol O, Sampaio C (2006) Review of the therapeutic management of Parkinson\u2019s disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson\u2019s disease. Eur J Neurol 13:1170\u20131185","journal-title":"Eur J Neurol"},{"key":"1860_CR11","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/archneur.64.5.676","volume":"64","author":"J Jankovic","year":"2007","unstructured":"Jankovic J, Watts RL, Martin W, Boroojerdi B (2007) Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 64:676\u2013682","journal-title":"Arch Neurol"},{"key":"1860_CR12","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1212\/01.wnl.0000259516.61938.bb","volume":"68","author":"PA LeWitt","year":"2007","unstructured":"LeWitt PA, Lyons KE, Pahwa R (2007) Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 68:1262\u20131267","journal-title":"Neurology"},{"key":"1860_CR13","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s00702-012-0925-5","volume":"120","author":"PA LeWitt","year":"2013","unstructured":"LeWitt PA, Boroojerdi B, Surmann E, Poewe W (2013) Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson\u2019s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER. J Neural Transm (Vienna) 120:1069\u20131081","journal-title":"J Neural Transm (Vienna)"},{"key":"1860_CR014","doi-asserted-by":"crossref","unstructured":"Nicholas AP, Borgohain R, Chan\u00e1 P, Surmann E, Thompson EL, Bauer L, Whitesides J, Elmer LW & SP921 Study Investigators (2014) A randomized study of rotigotine dose response on 'off' time in advanced Parkinson's disease. J Parkinsons Dis 4:361\u2013373","DOI":"10.3233\/JPD-130320"},{"key":"1860_CR14","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/mds.20887","volume":"21","author":"C Peralta","year":"2006","unstructured":"Peralta C, Wolf E, Alber H, Seppi K, Muller S, Bosch S, Wenning GK, Pachinger O, Poewe W (2006) Valvular heart disease in Parkinson\u2019s disease vs. controls: an echocardiographic study. Mov Disord 21:1109\u20131113","journal-title":"Mov Disord"},{"key":"1860_CR15","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2165\/11537810-000000000-00000","volume":"24","author":"S Perez-Lloret","year":"2010","unstructured":"Perez-Lloret S, Rascol O (2010) Dopamine receptor agonists for the treatment of early or advanced Parkinson\u2019s disease. CNS Drugs 24:941\u2013968","journal-title":"CNS Drugs"},{"key":"1860_CR16","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1002\/mds.23204","volume":"25","author":"S Perez-Lloret","year":"2010","unstructured":"Perez-Lloret S, Bondon-Guitton E, Rascol O, Montastruc JL (2010) Adverse drug reactions to dopamine agonists: a comparative study in the French Pharmacovigilance Database. Mov Disord 25:1876\u20131880","journal-title":"Mov Disord"},{"key":"1860_CR015","doi-asserted-by":"crossref","unstructured":"Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B & SP 515 Investigators (2007) Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6:513\u2013520","DOI":"10.1016\/S1474-4422(07)70108-4"},{"key":"1860_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa062222","volume":"356","author":"R Schade","year":"2007","unstructured":"Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29\u201338","journal-title":"N Engl J Med"},{"key":"1860_CR18","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1517\/14656566.2015.1049597","volume":"16","author":"L Timmermann","year":"2015","unstructured":"Timmermann L, Asgharnejad M, Boroojerdi B, Dohin E, Woltering F, Elmer LW (2015) Impact of 6-month earlier versus postponed initiation of rotigotine on long-term outcome: post hoc analysis of patients with early Parkinson\u2019s disease with mild symptom severity. Expert Opin Pharmacother 16:1423\u20131433","journal-title":"Expert Opin Pharmacother"},{"key":"1860_CR19","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/mds.27027","volume":"32","author":"N Titova","year":"2017","unstructured":"Titova N, Chaudhuri KR (2017) Personalized medicine in Parkinson\u2019s disease: time to be precise. Mov Disord 32:1147\u20131154","journal-title":"Mov Disord"},{"key":"1860_CR20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/mds.23441","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR (2011) Rotigotine effects on early morning motor function and sleep in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26:90\u201399","journal-title":"Mov Disord"},{"key":"1860_CR21","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1212\/01.wnl.0000252355.79284.22","volume":"68","author":"RL Watts","year":"2007","unstructured":"Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J (2007) Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 68:272\u2013276","journal-title":"Neurology"},{"key":"1860_CR22","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/j.1755-5922.2010.00169.x","volume":"29","author":"R Zanettini","year":"2011","unstructured":"Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2011) Regression of cardiac valvulopathy related to ergot-derived dopamine agonists. Cardiovasc Ther 29:404\u2013410","journal-title":"Cardiovasc Ther"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-018-1860-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-018-1860-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-018-1860-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T18:49:53Z","timestamp":1603910993000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-018-1860-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,26]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["1860"],"URL":"https:\/\/doi.org\/10.1007\/s00702-018-1860-x","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,26]]},"assertion":[{"value":"4 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Thomas M\u00fcller, Eduardo Tolosa, Letitia Badea, and Lars Timmermann were study investigators on this UCB Pharma-funded study. Letitia Badea has no other relevant disclosures. Thomas M\u00fcller was an advisor for UCB in relation to this project. Eduardo Tolosa received honoraria in the past 2\u00a0years for consultancy from TEVA, Bial, Accorda, Solvay, and Lundbeck, and has\u00a0received funding for research from the Spanish Network for Research on Neurodegenerative Disorders (CIBERNED), Instituto Carlos III (ISCIII), and The Michael J. Fox Foundation for Parkinson\u2019s Research (MJFF). Between April 2014 and April 2017, Lars Timmermann received payments as a consultant for Medtronic Inc., Boston Scientific, GE Medical, and UCB Schwarz Pharma. Lars Timmermann received honoraria as a speaker on symposia sponsored by Bial, Zambon Pharma, UCB Schwarz Pharma, Desitin Pharma, Medtronic, Boston Scientific, Abbott, and Bayer. The institution of Lars Timmermann, not Lars Timmermann personally, received funding by the German Research Foundation, the German Ministry of Education and Research, Manfred und Ursula M\u00fcller Stiftung, Kl\u00fch Stiftung, Hoffnungsbaum e. V., NBIA Disorders Society USA, K\u00f6ln Fortune, Medtronic, Deutsche Parkinson Vereinigung, Archimedes Pharma, Abbott, Bayer, UCB, Zur Rose Pharma, and TEVA. Neither Lars Timmermann nor any member of his family holds stocks, stock options, patents, or has financial interests in any of the above-mentioned companies or their competitors. Frank Grieger, Michael Markowitz, Xavier Nondonfaz, and Lars Bauer are salaried employees of UCB Pharma and receive stock options from their employment. Mahnaz Asgharnejad is a former employee of UCB Pharma and received restricted stock units from her employment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}